"Adenine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A purine base and a fundamental unit of ADENINE NUCLEOTIDES.
| Descriptor ID |
D000225
|
| MeSH Number(s) |
D03.633.100.759.138
|
| Concept/Terms |
Adenine- Adenine
- Vitamin B 4
- 4, Vitamin B
- B 4, Vitamin
|
Below are MeSH descriptors whose meaning is more general than "Adenine".
Below are MeSH descriptors whose meaning is more specific than "Adenine".
This graph shows the total number of publications written about "Adenine" by people in this website by year, and whether "Adenine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 1 | 1 |
| 1994 | 0 | 2 | 2 |
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 2 | 2 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 4 | 4 |
| 2001 | 0 | 1 | 1 |
| 2004 | 3 | 1 | 4 |
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 3 | 3 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 3 | 4 |
| 2015 | 4 | 1 | 5 |
| 2016 | 1 | 4 | 5 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 2 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 3 | 2 | 5 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adenine" by people in Profiles.
-
The dosing of ibrutinib and related Bruton's tyrosine kinase inhibitors: eliminating the use of brute force. Blood Adv. 2022 09 13; 6(17):5041-5044.
-
HRD1-mediated METTL14 degradation regulates m6A mRNA modification to suppress ER proteotoxic liver disease. Mol Cell. 2021 12 16; 81(24):5052-5065.e6.
-
Negative innovation: when patents are bad for patients. Nat Biotechnol. 2021 08; 39(8):914-916.
-
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Leukemia. 2021 10; 35(10):2854-2861.
-
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. Blood Cancer J. 2021 02 18; 11(2):39.
-
Ibrutinib's Cardiotoxicity-An Opportunity for Postmarketing Regulation. JAMA Oncol. 2021 02 01; 7(2):177-178.
-
Stabilization of ERK-Phosphorylated METTL3 by USP5 Increases m6A Methylation. Mol Cell. 2020 11 19; 80(4):633-647.e7.
-
LC-FACSeq is a method for detecting rare clones in leukemia. JCI Insight. 2020 06 18; 5(12).
-
Parallel Signaling through IRE1a and PERK Regulates Pancreatic Neuroendocrine Tumor Growth and Survival. Cancer Res. 2019 12 15; 79(24):6190-6203.
-
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. Oncology. 2019; 97(2):102-111.